An epidemic of icteric hepatitis in 1942 affected approximately 50,000 U.S. Army personnel. This outbreak was linked to specific lots of yellow-fever vaccine stabilized with human serum. To identify the responsible virus and the consequences of the epidemic, during 1985 we interviewed and serologically screened 597 veterans who had been in the army in 1942. These subjects were selected from three groups. Group I consisted of patients who had received the implicated vaccine and had jaundice; Group II had received the implicated vaccine but remained well; Group III had received a new, serum-free vaccine, with no subsequent jaundice. Ninety-seven percent of Group I, 76 percent of Group II, and 13 percent of Group III were positive for antibodies to hepatitis B virus. Only one subject had hepatitis B surface antigen, for a carrier rate of 0.26 percent among recipients of the implicated vaccine. The prevalence of hepatitis A antibody was similar in all three groups, and no subject had antibody to hepatitis delta virus. We conclude that hepatitis B caused the outbreak, that about 330,000 persons may have been infected, that the hepatitis B virus carrier state was a rare consequence, and that the outbreak induced hepatitis B antibodies that appear to persist for life.
This article has been cited by other articles:
Grabenstein, J. D., Pittman, P. R., Greenwood, J. T., Engler, R. J.M.
(2006). Immunization to Protect the US Armed Forces: Heritage, Current Practice, and Prospects. Epidemiol Rev
28: 3-26
[Abstract][Full Text]
Shepard, C. W., Simard, E. P., Finelli, L., Fiore, A. E., Bell, B. P.
(2006). Hepatitis B Virus Infection: Epidemiology and Vaccination. Epidemiol Rev
28: 112-125
[Abstract][Full Text]
Adrain, A. L., Ramberan, H., Weaver, G. J.
(2004). Evaluation of Common Liver Problems. J. Am. Podiatr. Med. Assoc.
94: 149-156
[Abstract][Full Text]
Mortimer, P. P
(2002). Yellow fever vaccine. BMJ
324: 439-439
[Full Text]
Dufour, D. R., Lott, J. A., Nolte, F. S., Gretch, D. R., Koff, R. S., Seeff, L. B.
(2000). Diagnosis and Monitoring of Hepatic Injury. I. Performance Characteristics of Laboratory Tests. Clin. Chem.
46: 2027-2049
[Abstract][Full Text]
Dufour, D. R., Lott, J. A., Nolte, F. S., Gretch, D. R., Koff, R. S., Seeff, L. B.
(2000). Diagnosis and Monitoring of Hepatic Injury. II. Recommendations for Use of Laboratory Tests in Screening, Diagnosis, and Monitoring. Clin. Chem.
46: 2050-2068
[Abstract][Full Text]
Dienstag, J. L., Schiff, E. R., Wright, T. L., Perrillo, R. P., Hann, H.-W. L., Goodman, Z., Crowther, L., Condreay, L. D., Woessner, M., Rubin, M., Brown, N. A., The U.S. Lamivudine Investigator Group,
(1999). Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States. NEJM
341: 1256-1263
[Abstract][Full Text]
Furmanski, M.
(1999). Unlicensed Vaccines and Bioweapon Defense in World War II. JAMA
282: 822-822
[Full Text]
Mahoney, F. J.
(1999). Update on Diagnosis, Management, and Prevention of Hepatitis B Virus Infection. Clin. Microbiol. Rev.
12: 351-366
[Abstract][Full Text]
Lemon, S. M., Thomas, D. L.
(1997). Vaccines to Prevent Viral Hepatitis. NEJM
336: 196-204
[Full Text]
